studies

es-BC - TNBC - NA - all population, durvalumab alone vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS) (extension)detailed resultsGeparNuevo, 2019 0.24 [0.03; 2.28] 0.24[0.03; 2.28]GeparNuevo, 201910%174NAnot evaluable pCR detailed resultsGeparNuevo, 2019 1.45 [0.80; 2.63] 1.45[0.80; 2.63]GeparNuevo, 201910%174NAnot evaluable AE leading to death (grade 5)detailed resultsGeparNuevo, 2019 0.89 [0.02; 45.40] 0.89[0.02; 45.40]GeparNuevo, 201910%174NAnot evaluable SAE (any grade)detailed resultsGeparNuevo, 2019 0.88 [0.47; 1.66] 0.88[0.47; 1.66]GeparNuevo, 201910%174NAnot evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed resultsGeparNuevo, 2019 1.79 [0.06; 54.10] 1.79[0.06; 54.10]GeparNuevo, 201910%174NAnot evaluable Abdominal pain AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.02; 45.40] 0.89[0.02; 45.40]GeparNuevo, 201910%174NAnot evaluable Alopecia AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.02; 45.40] 0.89[0.02; 45.40]GeparNuevo, 201910%174NAnot evaluable Anaemia AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.12; 6.46] 0.89[0.12; 6.46]GeparNuevo, 201910%174NAnot evaluable Arthralgia AE (grade 3-4)detailed resultsGeparNuevo, 2019 1.80 [0.16; 20.23] 1.80[0.16; 20.23]GeparNuevo, 201910%174NAnot evaluable Back pain AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.44 [0.01; 13.37] 0.44[0.01; 13.37]GeparNuevo, 201910%174NAnot evaluable Blood creatinine increased AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.05 [0.00; 0.89] 0.05[0.00; 0.89]GeparNuevo, 201910%174NAnot evaluable Constipation AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.05; 14.46] 0.89[0.05; 14.46]GeparNuevo, 201910%174NAnot evaluable Cough AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.02; 45.40] 0.89[0.02; 45.40]GeparNuevo, 201910%174NAnot evaluable Diarrhoea AE (grade 3-4)detailed resultsGeparNuevo, 2019 5.49 [0.27; 111.35] 5.49[0.27; 111.35]GeparNuevo, 201910%174NAnot evaluable Dry skin AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.02; 45.40] 0.89[0.02; 45.40]GeparNuevo, 201910%174NAnot evaluable Dyspnoea AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.02; 45.40] 0.89[0.02; 45.40]GeparNuevo, 201910%174NAnot evaluable Epistaxis AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.02; 45.40] 0.89[0.02; 45.40]GeparNuevo, 201910%174NAnot evaluable Fatigue AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.47 [0.15; 1.45] 0.47[0.15; 1.45]GeparNuevo, 201910%174NAnot evaluable Febrile neutropenia AE (grade 3-4)detailed resultsGeparNuevo, 2019 1.82 [0.32; 10.20] 1.82[0.32; 10.20]GeparNuevo, 201910%174NAnot evaluable Headache AE (grade 3-4)detailed resultsGeparNuevo, 2019 1.79 [0.06; 54.10] 1.79[0.06; 54.10]GeparNuevo, 201910%174NAnot evaluable Hyperthyroidism AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.02; 45.40] 0.89[0.02; 45.40]GeparNuevo, 201910%174NAnot evaluable Hypophysitis AE (grade 3-4)detailed resultsGeparNuevo, 2019 1.79 [0.06; 54.10] 1.79[0.06; 54.10]GeparNuevo, 201910%174NAnot evaluable Hypothyroidism AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.02; 45.40] 0.89[0.02; 45.40]GeparNuevo, 201910%174NAnot evaluable Increase AST AE (grade 3-4)detailed resultsGeparNuevo, 2019 5.49 [0.27; 111.35] 5.49[0.27; 111.35]GeparNuevo, 201910%174NAnot evaluable Increased ALT AE (grade 3-4)detailed resultsGeparNuevo, 2019 1.20 [0.26; 5.51] 1.20[0.26; 5.51]GeparNuevo, 201910%174NAnot evaluable Infusion-related reaction AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.02; 45.40] 0.89[0.02; 45.40]GeparNuevo, 201910%174NAnot evaluable Injury, poisoning and procedure AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.05; 14.46] 0.89[0.05; 14.46]GeparNuevo, 201910%174NAnot evaluable Leucopenia AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.84 [0.45; 1.57] 0.84[0.45; 1.57]GeparNuevo, 201910%174NAnot evaluable Myalgia AE (grade 3-4)detailed resultsGeparNuevo, 2019 1.82 [0.32; 10.20] 1.82[0.32; 10.20]GeparNuevo, 201910%174NAnot evaluable Nausea AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.06 [0.00; 1.05] 0.06[0.00; 1.05]GeparNuevo, 201910%174NAnot evaluable Neutropenia AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.83 [0.45; 1.52] 0.83[0.45; 1.52]GeparNuevo, 201910%174NAnot evaluable Peripheral neuropathy AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.88 [0.33; 2.33] 0.88[0.33; 2.33]GeparNuevo, 201910%174NAnot evaluable Pneumonitis AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.02; 45.40] 0.89[0.02; 45.40]GeparNuevo, 201910%174NAnot evaluable Rash AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.05; 14.46] 0.89[0.05; 14.46]GeparNuevo, 201910%174NAnot evaluable Stomatitis AE (grade 3-4)detailed resultsGeparNuevo, 2019 3.62 [0.16; 81.50] 3.62[0.16; 81.50]GeparNuevo, 201910%174NAnot evaluable Thrombocytopenia AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.44 [0.04; 4.94] 0.44[0.04; 4.94]GeparNuevo, 201910%174NAnot evaluable Vomiting AE (grade 3-4)detailed resultsGeparNuevo, 2019 0.89 [0.05; 14.46] 0.89[0.05; 14.46]GeparNuevo, 201910%174NAnot evaluable0.010.01.0relative treatment effectwww.metaEvidence.org2024-10-31 23:52 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 305 - treatments: 374